The OraQuick in-home HIV-1/2 antibody test was granted market clearance by the FDA on May 15, 2012. Data presented included a < 0.1% false-positive rate and 91.7% sensitivity to correctly detect HIV infection compared to conventional ELISA performed on blood.
Supplemental grape resveratrol appears to improve both inflammatory and fibrinolytic markers in patients who are on statin therapy for primary prevention of cardiovascular disease.
Clinical Briefs: Refining the Relationship Between Thyroid Hormones and Left Ventricular Mass; The ORIGIN Trial: Basal Insulin vs Standard Care for Early Type 2 Diabetes; Bronchodilators in COPD and Arrhythmias
